SCHEMBL6201289

SCHEMBL6201289

COc1ccc(C(=O)C(Br)c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
CYP1A2 P05177 1/20 0.61
MAPT P10636 5/20 0.60
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
POLB P06746 2/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
CES2 O00748 3/20 0.56
CES1 P23141 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
LMNA P02545 3/20 0.53
MITF O75030 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HIF1A Q16665 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
ACP3 P15309 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7017619 0.93 ALDH1A1 (0.57) ALDH1A1CYP1A2MAPTNPC1RAB9A
SCHEMBL3089210 0.91 ALDH1A1 (0.62) ALDH1A1CYP1A2MAPTNPC1RAB9A
SCHEMBL15096860 0.91 ALDH1A1 (0.59) ALDH1A1CYP1A2MAPTNPC1RAB9A
SCHEMBL15092882 0.91 ALDH1A1 (0.59) ALDH1A1CYP1A2MAPTNPC1RAB9A
SCHEMBL10824473 0.86 CES2 (0.52) ALDH1A1CYP1A2MAPTNPC1RAB9A
SCHEMBL3105019 0.85 ALDH1A1 (0.55) ALDH1A1CYP1A2MAPTNPC1RAB9A
SCHEMBL2150940 0.85 ALDH1A1 (0.55) ALDH1A1CYP1A2MAPTNPC1RAB9A
SCHEMBL6210392 0.85 RAB9A (0.58) ALDH1A1MAPTNPC1RAB9APOLB
SCHEMBL6208904 0.85 RAB9A (0.58) ALDH1A1MAPTNPC1RAB9APOLB
SCHEMBL3092612 0.84 HPGD (0.60) ALDH1A1CYP1A2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139543-B2 Thiazole compounds and uses thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-09-22 US disclosed
US-20150119430-A1 Thiazole Compounds and Uses Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-04-30 US disclosed
US-20050272036-A1 Ketones ASTRAZENECA AB (SE) 2005-12-08 US disclosed
EP-1549600-A1 KETONES AstraZeneca AB (SE) 2005-07-06 EP disclosed
WO-2004011410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-02-05 WO disclosed
EP-0733633-B1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-05-28 EP disclosed
US-5753664-A ANTITUMOR AGENTS, PYRIMIDONES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-05-19 US disclosed
EP-0733633-A1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119430-A1 Thiazole Compounds and Uses Thereof BAX, TNNT2, TNNI3 ALDH1A1 1137/4885CYP1A2 2730/4885MAPT 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.